Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
AssigneeCuRNA, Inc.
InventorsJoseph Collard, Olga Khorkova Sherman
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense polynucleotides of Interferon Regulatory Factor 8 (IRF8). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRF8.
Claims13
A method of upregulating a function of and/or the expression of a Interferon Regulatory Factor 8 (IRF8) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one modified antisense oligonucleotide 12 to 30 nucleotides in length wherein said at least one oligonucleotide is specific for and targets a natural antisense polynucleotide of the IRF8 gene and has identity to a reverse complement of a polynucleotide comprising 12 to 30 consecutive nucleotides within nucleotides 1 to 312 of SEQ ID NO:
- 2 thereby upregulating a function of and/or the expression of the Interferon Regulatory Factor 8 (IRF8) polynucleotide in patient cells or tissues in vivo or in vitro.
A method of upregulating a function of and/or the expression of a Interferon Regulatory Factor 8 (IRF8) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one single stranded modified antisense oligonucleotide of 12 to 30 nucleotides in length that specifically targets a complementary region of a natural antisense polynucleotide of the Interferon Regulatory Factor 8 (IRF8) polynucleotide selected from SEQ ID NO 2;
- thereby upregulating a function of and/or the expression of the Interferon Regulatory Factor 8 (IRF8) polynucleotide in patient cells or tissues in vivo or in vitro.
A method of upregulating a function of and/or the expression of Interferon Regulatory Factor 8 (IRF8) in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one modified antisense oligonucleotide of about 12 to 30 nucleotides in length specific for noncoding sequences of a natural antisense strand of a Interferon Regulatory Factor 8 (IRF8) polynucleotide wherein said at least one antisense oligonucleotide has sequence identity to at least one nucleic acid sequence set forth as SEQ ID NOS:
- 1 or an RNA polynucleotide encoded by the IRF8 gene;
- and, upregulating the function and/or expression of the Interferon Regulatory Factor 8 (IRF8) in mammalian cells or tissues in vivo or in vitro.
A method of treating a disease associated with at least one Interferon Regulatory Factor 8 (IRF8) polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient a therapeutically effective dose of at least one modified antisense oligonucleotide of 12 to 30 nucleotides in length that specifically binds to a natural antisense sequence of said at least one Interferon Regulatory Factor 8 (IRF8) polynucleotide and upregulates expression of said at least one Interferon Regulatory Factor 8 (IRF8) polynucleotide;
- thereby treating the disease associated with the at least one Interferon Regulatory Factor 8 (IRF8) polynucleotide and/or at least one encoded product thereof.
Dependencies are inferred from the claim text.